-
Jun.042020NEWS
HanAll Biopharma Appoints Sean Jeong as CEO of HPI, HanAll’s US Subsidiary
HanAll Biopharma Appoints Sean Jeong as CEO of HPI, HanAll’s US Subsidiary
-
Apr.222020NEWS
HBM, HanAll Biopharma’s Chinese Partner, Begins Clinical Trials for Batoclimab with NMOSD Patients
HBM, HanAll Biopharma’s Chinese Partner, Begins Clinical Trials for Batoclimab with NMOSD Patients
-
Mar.312020NEWS
Immunovant, HanAll’s partner, Announces Topline data from Phase 2 for IMVT-1401 in TED
Immunovant, HanAll’s partner, Announces Topline data from Phase 2 for IMVT-1401 in TED
-
Feb.272020NEWS
HanAll Biopharma Recorded Its Record-High Earnings Last Year
HanAll Biopharma Recorded Its Record-High Earnings Last Year
-
Jan.282020NEWS
HanAll Biopharma/Daewoong Announces Topline Results for HL036 Phase 3(VELOS-2) Study at a Press Conference
HanAll Biopharma/Daewoong Announces Topline Results for HL036 Phase 3(VELOS-2) Study at a Press Conf..
-
Mar.122019NEWS
HanAll Biopharma Begins Phase III Clinical Trial of HL036 in Patients with Dry Eye Disease
HanAll Biopharma Begins Phase III Clinical Trial of HL036 in Patients with Dry Eye Disease